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Poly Cystic Ovarian Syndrome (PCOS) is one of the most common metabolic and
reproductive disorders among women of reproductive age. Women suffering from
PCOS present with a constellation of symptoms associated with menstrual dysfunction
and androgen excess, which significantly impacts their quality of life. They may be
at increased risk of multiple morbidities, including obesity, insulin resistance, type II
diabetes mellitus, cardiovascular disease (CVD), infertility, cancer, and psychological
disorders. This review summarizes what the literature has so far provided from guidelines
to diagnosis of PCOS. It will also present a general overview about the morbidities
associated with this disease, specifically with its more severe classic form. Finally, the
review will stress on the various aspects of treatment and screening recommendations
currently used in the management of this condition.
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INTRODUCTION
Polycystic Ovarian Syndrome (PCOS), also referred to as hyperandrogenic anovulation (HA), or
Stein–Leventhal syndrome (Evans and Riley, 1958), is one of the most common endocrine system
disorders that affect women in their reproductive age (Azziz et al., 2004). Described since 1935 by
Stein and Leventhal (1935), it represents a condition in which an estimate of 10 small cysts of a
diameter ranging between 2 and 9 mm develop on one or both ovaries and/or the ovarian volume
in at least one ovary exceeds 10 ml (Balen and Rajkowha, 2003).
Systematic screening of women according to the National Institutes of Health (NIH) diagnostic
criteria estimated that 4–10% of women of reproductive age suffer from PCOS (Azziz et al., 2004).
Although it was previously considered as a disorder of adult women, recent evidence suggests that
PCOS is a lifelong syndrome, manifesting since prenatal age. In fact, according to the Rotterdam
diagnostic criteria, the prevalence of PCOS in adolescents varies between a minimum of 3%
(Hashemipour et al., 2004) and a maximum of 26% (Driscoll, 2003). However, the prevalence of
the disease in children is still considered unknown (Kamangar et al., 2015).
The economic burden of PCOS is significantly huge. Around 4 billion dollars are spent annually
in the United States to screen for the disease and treat its various morbidities, including hirsutism,
infertility, and diabetes mellitus (Azziz et al., 2005). The Australian Health System spends more
than 800million dollars every year to account for the disease (Azziz et al., 2005). Patients with PCOS
are twice more likely to be admitted to hospital in comparison to patients without it (Hart and
Doherty, 2015). Therefore, accurate and early diagnosis of PCOS is necessary not only to prevent
future health comorbidities but also to reduce financial cost and burden (Kamangar et al., 2015).
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In this review, we will summarize the most relevant and recent
reports related to PCOS, briefly addressing the pathophysiology
of the disease, then dwelling in more depth into its diagnostic
criteria and their limitations in adolescence. Moreover, we will
discuss morbidities associated with the classic form of PCOS
and we will provide information about the various treatment
regimens and screening recommendations for women living with
this condition. Throughout the review, we will emphasize the
complexity of PCOS in terms of pathophysiology, diagnosis,
morbidities, and the multidisciplinary treatment approach it
requires.
PATHOPHYSIOLOGY
Previous Hypotheses
Many hypotheses emerged trying to explain the pathophysiology
of PCOS. Initially, excess intrauterine androgen had been
thought to be a main culprit in the development of the
disease. Yet recently, human studies showed neither an
association between excessive prenatal androgen exposure and
the development of PCOS in youth (Hickey et al., 2009)
nor an elevation in androgen levels in the cord blood
of females born to mothers with PCOS (Anderson et al.,
2010). Another hypothesis, the adipose tissue expandability
hypothesis, suggested that infants with intra-uterine growth
restriction (IUGR) and spontaneous catch-up growth might
develop decreased tissue expandability, meaning that they cannot
store lipids appropriately in their fat tissues. Consequently,
insulin resistance might ensue contributing to PCOS and
hyperandrogenemia (de Zegher et al., 2009). However, this does
not apply for patients with PCOS who did not have IUGR or had
it but without spontaneous catch up growth (Ibáñez et al., 1998,
2009).
A Multifaceted Disease
The best understanding of the pathophysiology of PCOS deals
with it as a multifaceted disease involving uncontrolled ovarian
steroidogenesis, aberrant insulin signaling, excessive oxidative
stress, and genetic/environmental factors.
An intrinsic defect in theca cells can partially explain the
hyperandrogenemia in patients with PCOS. Indeed, women with
PCOS have theca cells that, still secrete high levels of androgens
due to an intrinsic activation of steroidogenesis even in the
absence of trophic factors (Nelson et al., 1999). This intrinsic
dysregulation also affects granulosa cells which produce up to
4 times higher levels of anti-mullerian hormone in women
with PCOS in comparison to healthy controls (Pellatt et al.,
2007; Azziz et al., 2009; Villarroel et al., 2011). Studies also
show an elevated number of follicles, primarily pre-antral and
small antral follicles, in females with PCOS (Webber et al.,
2003). A defect in apoptotic processes in some maturing follicles
further increases their count in PCOS patients (Das et al.,
2008).
Alternatively, decreased insulin sensitivity attributable to a
postreceptor binding defect in the insulin signaling pathways
has been identified as an intrinsic component of PCOS,
independent of obesity (Dunaif, 1997). It was also reported
an alteration in gene expression of some players in insulin
signaling pathways by microarray gene analysis (Cortón
et al., 2007, 2008). Moreover, PCOS has been associated
with increased glycooxidative stress (González et al., 2006)
secondary to mitochondrial dysfunction (Victor et al., 2009).
Oxidative stress can itself induce insulin resistance and
hyperandrogenism in patients with PCOS (Victor et al.,
2009).
Familial aggregation of PCOS (Azziz et al., 2004; Chen et al.,
2011) and genomic identification of PCOS-susceptibility loci
(Chen et al., 2011) support the role of genetics in the etiology
of this disease. Some studies showed an inherited component
of androgen excess in patients with PCOS (Legro et al., 1998;
Escobar-Morreale et al., 2005; Yildiz et al., 2006). Furthermore,
a polymorphic marker in fibrillin 3 gene associated with PCOS,
D19S884, has been identified in independent sets of families
carrying the disease (Urbanek et al., 2007; Segars and Decherney,
2010).
Evolution
Recently, multiple studies are suggesting that PCOS might start
in utero, mainly in neonates with risk factors implicated in the
development of PCOS. This includes low birth weight (Ibáñez
et al., 1998; Melo et al., 2010) and high birth weight infants
(Cresswell et al., 1997) who later on catch-up on their growth
or constantly increase in weight postnatally (de Zegher and
Ibáñez, 2009). Such risk factors, along with a susceptible genetic
component, can lead to signs of premature pubarche, premature
adrenarche (elevated DHEAS), and metabolic syndrome (insulin
resistance and visceral adiposity) (Verkauskiene et al., 2007;
Ibáñez et al., 2009). In adolescence, the disease will switch
to its more common form with signs and symptoms of
hyperandrogenism and/or anovulation. Later on, throughout
adulthood, the picture may evolve to any of the various PCOS
phenotypes (Rotterdam, 2004). Long termmorbidities, including
cardiovascular disease (CVD), tend to be more prevalent in
the postmenopausal period (Shaw et al., 2008; Wang et al.,
2011).
The presentation of PCOS as a model that undergoes a step-
wise evolution throughout development puts the complexity
of this disease into perspective. Indeed, although science has
provided an insight into the origins of PCOS, our understanding
of it is still lacking. For instance, the adipose tissue expandability
hypothesis cannot account for the disease in infants without
IUGR. And since uncontrolled ovarian steroidogenesis that
causes hyperandrogenism forms one aspect of the disease, how
can we explain the lack of correlation between prenatal androgen
exposure and the development of PCOS in humans? Should
excessive androgen exposure occur at a susceptible growth
window for PCOS to manifest in the future? If this is true, what
is the age interval of this susceptibility window? How is the
genetic component of the disease inherited and does it exhibit
penetrance? Could we possibly, 1 day, screen neonates for PCOS?
Supplementary studies are definitely required to shed light over
the missing links between the ovarian dysregulation, androgen
excess, genetics, and various susceptibility factors that might
contribute to PCOS.
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DIAGNOSIS
Guidelines
Diagnosis of PCOS in adults can follow three different guidelines,
which criteria are described in Figure 1. Even though conditions
such as insulin resistance and obesity are considered intrinsic to
PCOS, none of them is included in the guidelines and should
therefore be used for diagnostic purposes (Witchel et al., 2015).
In addition to the information described in Figure 1, each
of the guidelines requires ruling out any pathological condition
that might explain the hyperandrogenism or the menstrual
irregularity (Powers et al., 2015). The disparity between the
guidelines, although minor, has been associated with a variation
in the diagnosis and the treatment of PCOS (Powers et al., 2015).
Moreover, diagnosis in adolescent females is highly debatable
(Siklar et al., 2015).
Signs and Symptoms
The symptomatic presentation of PCOS usually varies with
age, young women mainly complaining of reproductive and
psychological problems while older women complaining of
metabolic symptoms (Teede et al., 2011). Figure 2 describes
signs, symptoms, and laboratory values common in patients
with PCOS. A thorough physical examination, medical history,
and laboratory tests should be conducted to reach the
appropriate diagnosis (Witchel et al., 2015). Discontinuation
of spironolactone and oral contraceptive pills (OCP) around 1
month prior to testing, along with testing near the luteal phase
of the menstrual cycle are recommended for more accurate
results. In addition, on the one hand, testing should include
an assessment of the metabolic status of the patient, i.e.,
measurement of her body mass index (BMI), conduction of a
fasting lipid panel, and a 2-h glucose challenge test. On the
other hand, screening for thyroid disorders through assessment
of thyroid-stimulating hormone levels is considered important as
thyroid disorders are a common cause of menstrual irregularity
(Kamangar et al., 2015).
Phenotypes
Since PCOS tends to present as a spectrum of diseases, the
Rotterdam criteria divided the disease into four phenotypes
(Rotterdam, 2004):
â Frank or classic polycystic ovary PCOS (chronic anovulation,
hyperandrogenism, and polycystic ovaries)
â Classic non-polycystic ovary PCOS (chronic anovulation,
hyperandrogenism, and normal ovaries)
â Non-classic ovulatory PCOS (regular menstrual cycles,
hyperandrogenism, and polycystic ovaries)
â Non-classic mild or normoandrogenic PCOS (chronic
anovulation, normal androgens, and polycystic ovaries)
Women with the frank phenotype have a worse profile of
metabolic and cardiovascular risk factors (i.e., higher insulin
resistance and poorer lipid panel) than those with the non-classic
phenotype, even when the comparison and the control groups
have a comparable BMI (Diamanti-Kandarakis and Panidis,
2007). Likewise, evidence suggests that the frank phenotype
may predict a higher rate of postmenopausal cardiovascular
morbidity and mortality in comparison to the non-classic
phenotype (Shaw et al., 2008). In contrast, women with non-
classic normoandrogenic phenotype have less insulin resistant
and tend to lack the metabolic features of PCOS in comparison
to their counterparts with the classic frank phenotype (Diamanti-
Kandarakis and Panidis, 2007; Goverde et al., 2009; Zhang et al.,
2009). In this review, the “Associated Morbidities” section will
shed light over the complications mostly seen in the classic
phenotypes of PCOS rather than in the non-classic ones.
The variation in the symptomatology and presentation of
PCOS can account for the presence of different diagnostic
guidelines, as the phenotype may vary from being asymptomatic
to having signs of all 3 components of the disease (anovulation,
hyperandrogenism, and polycystic ovaries). One can argue that
the different guidelines might lead to under-diagnosis or over-
diagnosis of this condition. This clearly underlines the need for
one new single guideline which encompasses all the different
phenotypes of PCOS without missing the milder forms of the
disease.
CHALLENGES IN DIAGNOSIS IN
ADOLESCENTS
Held in Amsterdam in 2012, the third PCOS Consensus
workshop meeting reported that the diagnosis of PCOS in
adolescents should meet the Rotterdam criteria and is therefore
similar to the diagnostic features in adults. However, diagnostic
practices for adolescents with PCOS tend to be inconsistent and
variable among endocrinologists and gynecologists. Diagnosing
PCOS in children and adolescence is challenging because
the normal pubertal physiological events tend to mimic the
signs and symptoms of PCOS (Legro, 2015). This overlap
between normal puberty and the diagnostic pathological criteria
of PCOS may cause an over-diagnosis of PCOS among
adolescent girls (Witchel et al., 2015) which can lead to
unnecessary treatment and psychological impairment (Powers
et al., 2015).
Hyperandrogenism
Puberty is characterized by physiological hyperandrogenism
(Kahsar-Miller et al., 2001). Multiple studies showed that
testosterone levels rise during puberty and reach a peak adult
level within a few years after menarche. This can confound
with pathological hyperandrogenism and therefore cloud the
picture of PCOS (Moll and Rosenfield, 1983; Van Hooff et al.,
2000; Mortensen et al., 2009; Rosenfield, 2013). Measurement
of testosterone levels does not resolve this uncertainty because
testosterone concentrations are highly influenced by the stage
of puberty and the menstrual cycle along with other factors
(Witchel et al., 2015). In addition, no cutoff values or reference
ranges for androgen levels are well defined in female adolescents
(Legro et al., 2013). Moreover, acne, which is largely seen
during puberty, is not correlated with hyperandrogenism
(Hickey et al., 2011). Furthermore, diagnosing hirsutism is
challenging since the standardized scoring value does not take
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FIGURE 1 | Guidelines for the diagnosis of PCOS (Rotterdam, 2004; Azziz et al., 2006).
FIGURE 2 | Signs and symptoms in patients with PCOS (Rotterdam, 2004; Chhabra et al., 2005; Legro et al., 2013).
into consideration ethnic variations (Ferriman and Gallwey,
1961).
Menstrual Irregularity
Adolescents frequently exhibit physiological menstrual
irregularities such as oligomenorrhea (Powers et al., 2015),
usually during the first 2 years after menarche, due to lack
of maturation of hypothalamic-hypopituitary-ovarian axis
(Tfayli and Arslanian, 2008). As such, menstrual irregularity
can be sometimes an unreliable criterion for diagnosis of
PCOS in adolescents (Kamangar et al., 2015). Through close
observation of the menstrual cycle patterns, clinicians have to
differentiate physiological anovulation associated with puberty
from pathological anovulation as a dysfunction identified in
PCOS (Franks, 2002; Wiksten-Almstromer et al., 2008). It has
been suggested to postpone diagnosis at least 2 years after
menarche to establish a persistent menstrual irregularity (Hardy
and Norman, 2013). However, this may delay the initiation of
appropriate treatment (Powers et al., 2015).
Polycystic Ovaries on Ultrasonography
Normal physiological changes and variations in the volume
and size of the ovaries during puberty make ultrasonography
findings controversial for the diagnosis of PCOS (Dewailly
et al., 2014). Also, performing a transrectal or transvaginal
ultrasonography in adolescents may not be always applicable,
which may delay diagnosis (Venturoli et al., 1995). For diagnostic
purposes, normal ovarian volume in female adolescents is
considered equal to or less than 10 ml (Carmina et al.,
2010).
ASSOCIATED MORBIDITIES
Obesity
Obesity is considered one of the most important features of
PCOS. Its prevalence in diseased women varies between 61 and
76% (Glueck et al., 2005). The prevalence of obesity reaches 80%
in the United States (Ehrmann et al., 1999) and 50% outside
(Balen et al., 1995) which indicates that this figure depends on
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local environmental factors, ethnic backgrounds, and lifestyle,
and not on the mere presence of PCOS itself.
Childhood obesity is a well-documented risk factor for PCOS.
Obese girls are at a higher risk of developing insulin resistance,
metabolic syndrome, and PCOS later on in life (Pasquali et al.,
2011). On the other hand, women with PCOS are at a higher
risk of developing obesity (Randeva et al., 2012). Many studies
explain that females with PCOS have increased visceral and
subcutaneous body fat distribution due to increased androgen
production rates (Kirschner et al., 1990); this central obesity
follows a masculinized body fat distribution (Borruel et al.,
2013) where the amount of visceral fat correlates with the
degree of insulin resistance (Karabulut et al., 2012). Moreover,
obesity plays a significant role in expressing the metabolic
features of PCOS. Women with PCOS have an atherogenic lipid
profile, associated with elevated levels of low-density lipoprotein,
triglycerides and cholesterol, along with decreased levels of
high-density lipoprotein. They are also at a higher risk of
developing atherosclerosis, arterial stiffness, and altered vascular
endothelium (Hart and Norman, 2006). In addition, women with
PCOS show a worsened cardiovascular profile and associated
complications (Randeva et al., 2012). However, obesity by itself is
not the main reason behind these features. This is evident in lean
women with PCOSwho demonstrate the samemetabolic features
as those who are obese (Balen et al., 1995).
Whether obesity leads to PCOS or whether PCOS leads to
obesity is still debatable (Kamangar et al., 2015). In animal
models of PCOS, administration of testosterone in pregnant rats
andmonkeys during early conception causes a central abdominal
accumulation of fat of the progeny in postpartum life. Hence,
prenatal androgen surplus, whether genetic or induced, might
be the primordial event in the development of PCOS associated
obesity (Escobar-Morreale et al., 2012) yet does not imply that
PCOS will ultimately ensue.
Insulin Resistance
A great deal of attention has been given to the metabolic
disturbances that accompany PCOS, as well as to the
consequences of these disturbances later in life. Today,
insulin resistance is considered the main pathogenic factor in the
background of increased metabolic disturbances in women with
PCOS (Siklar et al., 2015) which can explain hyperandrogenism,
menstrual irregularity, and other metabolic manifestations seen
in this disease (Baillargeon et al., 2003; Diamanti-Kandarakis
and Dunaif, 2012).
In 1980, the association between hyperinsulinemia and PCOS
was first noted by Burghen et al. who found a significant positive
correlation between insulin, androstenedione and testosterone
levels among PCOS women (Burghen et al., 1980). In fact,
recent studies show that hyperinsulinemia is present in 85%
of patients with PCOS, including 95% of obese and 65% of
lean affected women (Teede et al., 2010, 2011; Stepto et al.,
2013). Increased insulin levels in patients with PCOS may, along
with the high levels of luteinizing hormone, trigger the arrest
of follicular growth which contributes to anovulation (Dunaif,
1995). Hyperinsulinemia also alters the gonadotropin-releasing
hormone (GnRH) pulse secretion pattern, suppresses the sex
hormone-binding globulin (SHBG) and potentiates ovarian
androgen production in women with PCOS (Bhattacharya and
Jha, 2011; Hart et al., 2011; Huang et al., 2011; Lass et al., 2011;
Rathsman et al., 2012; Wedin et al., 2012).
Multiple studies supported a correlation between diabetes
and PCOS and showed that insulin-sensitizing drugs and
dietary/lifestyle modifications improve hyperandrogenism in
patients suffering from PCOS (Baillargeon et al., 2003; Diamanti-
Kandarakis and Dunaif, 2012). When the hormone leptin
is used as insulin-sensitizing agent, it decreases androgen
levels and induces menstruation in affected lean women
(Lungu et al., 2012). Other studies showed that 6 months
of lifestyle modifications enhanced insulin sensitivity by
70% and significantly reduced anovulation in affected obese
women (Baillargeon et al., 2003; Diamanti-Kandarakis and
Dunaif, 2012). These studies provide support that insulin
resistance aggravates hyperandrogenemia (Lungu et al., 2012).
This is one of the critical junctures in the treatment of
PCOS, which led to the consideration of insulin-mimetic
or insulin-sensitizing agents as part of the management
of the disease. These agents, as mentioned later in the
review, include metformin, myo-inositol supplements, and
thiazolidinedione.
Finally, according to the Diabetes Prevention Program (DPP)
Research Group (2002), PCOS patients should be tested for
insulin resistance. A few biomarkers have been used to detect
insulin resistance in PCOS women. For instance, insulin restrains
the release of sex hormone binding globulin (SHBG) from the
liver and the production of insulin-like growth factor binding
protein 1 (IGFBP-1) (Kalme et al., 2003). It also affects the
homeostatic model assessment (HOMA-IR) which is based on
computations of fasting glucose and levels of insulin (Legro
et al., 2004). Yet, different markers have variable sensitivities and
specificities in insulin resistance testing (Nawrocka-Rutkowska
et al., 2013). Thus, research should identify one universal marker
for accurate diagnosis of decreased insulin sensitivity in patients
with PCOS. If such a marker is identified, early detection of
insulin resistance can lead to prompt treatment and prevention
of any complications in the future.
Type II Diabetes Mellitus
PCOS confers a substantially increased risk for type 2 diabetes
mellitus and gestational diabetes from early ages (Randeva
et al., 2012). About 1 in 5 women with PCOS will develop
type II diabetes (Dunaif, 1999) making impaired glucose
tolerance a common abnormality in this disease (Randeva et al.,
2012). Cross-sectional and prospective longitudinal studies have
consistently shown that women suffering from PCOS have a
higher risk of developing type II diabetes mellitus or impaired
glucose tolerance compared to control populations matched for
age and ethnic background (Ehrmann et al., 1999; Legro et al.,
1999, 2005; Boudreaux et al., 2006; Talbott et al., 2007; Lerchbaum
et al., 2013). Furthermore, prospective longitudinal studies in
young andmiddle-aged womenwith PCOS show a higher risk for
developing diabetes later in life and is mainly due to an increased
prevalence of obesity and insulin resistance among these patients
(Dunaif, 1999).
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Interestingly, family history of diabetes increases the
prevalence of type II diabetes mellitus in PCOS patients.
However, the prevalence of diabetes in PCOS patients with no
family history of diabetes was still much higher than normal
women (Ehrmann et al., 1995). Even though family history
and obesity are major contributors in the development of
diabetes in PCOS patients, diabetes can still occur in lean PCOS
patients who have no family history, mainly secondary to insulin
resistance (Dunaif, 1999).
Cardiovascular Disease
In 1992, Dahlgren et al. identified a 7 times higher risk of
myocardial infarction in patients with PCOS compared to
healthy controls (Dahlgren et al., 1992). However, in 1998, an
epidemiological study by Pierpoint et al. showed no difference in
the risk between the two groups (Pierpoint et al., 1998).
More recent data showed that patients with PCOS have
significantly elevated levels of circulating biomarkers of CVD,
including C-reactive protein (Bahceci et al., 2004; Meyer et al.,
2005) and lipoprotein A (Yilmaz et al., 2005; Bahceci et al.,
2007; Berneis et al., 2009; Rizzo et al., 2009), in comparison to
matched controls. Other studies demonstrated a higher burden
of indicators of atherosclerosis with early onset cardiovascular
dysfunction, i.e., arterial stiffness, endothelial dysfunction, and
coronary artery calcification (Meyer et al., 2005; Moran et al.,
2009).
In 2010, the Androgen Excess-PCOS society provided a
consensus statement about increased risk of CVD in women with
PCOS and developed a guideline to prevent such complication
(Wild et al., 2010). Yet, despite the increased cardiovascular
risk markers and the indubitable presence of CVD risk factors
in this population, uncertainty remains regarding the increased
cardiovascular morbidity and mortality in patients with PCOS
(Legro, 2003; Wild et al., 2010; Schmidt et al., 2011; Sathyapalan
and Atkin, 2012). Discrepancy between studies might be due to
the heterogeneous nature of the populations studied. Therefore,
supplementary methodologically rigorous trials are needed to
determine the absolute risk of CVD in patients with PCOS
throughout age ranges.
Infertility
Women with PCOS may have reduced fertility (Hart and
Norman, 2006; Hart and Doherty, 2015) due to the associated
endocrine and gynecologic abnormalities that impact ovarian
quality and function (Hart and Norman, 2006). Accounting for
up to 90% of ovulatory disorders (Hull, 1987), PCOS-associated
persistent periods of anovulation are positively correlated with
infertility (Imani et al., 1998). In 1995, a study reported up to
50 and 25% of women in a PCOS population suffering from
primary and secondary infertility respectively (Balen et al., 1995).
More recently in 2015, a study by Hart and Doherty showed that
infertility is 10 times more common among women with PCOS
in comparison to healthy controls (Hart and Doherty, 2015).
On the other hand, some studies suggested that females
with PCOS who conceive might suffer from pregnancy-related
complications such as gestational diabetes (Bruyneel et al., 2014),
pregnancy induced hypertension (Hu et al., 2007; Sir-Petermann
et al., 2012; Bruyneel et al., 2014), and preeclampsia (Katulski
et al., 2015) to a higher extent in comparison to matched
controls. Various research data also suggest an increased risk of
miscarriage in women with PCOS (Balen et al., 1993; Homburg
et al., 1993; Wang et al., 2001; Winter et al., 2002).
The influence of PCOS phenotype, whether classic or non-
classic, on female fertility remains poorly comprehended. Data
describing the effects of PCOS on pregnancy outcomes are also
limited and based on small trials. Thorough studies are needed
to assess the degree of infertility in PCOS various phenotypes
and to understand the reasons for increased negative pregnancy
outcomes in this group of women.
Concerning the effects on the embryo, women with PCOS are
2.5 times at a higher risk of giving birth to small for gestational
age children in comparison to healthy females (Katulski et al.,
2015) and offspring show an increased morbidity and mortality
compared to control (Fauser et al., 2012).
Cancer
Females suffering from PCOS present many risk factors
associated with the development of endometrial cancer, such
as obesity, insulin resistance, type II diabetes mellitus, and
anovulation (Legro et al., 2013). Anovulation triggers an
unopposed uterine estrogen exposure. This can subsequently
trigger the development of endometrial hyperplasia and
ultimately endometrial cancer (Hart and Norman, 2006).
As a matter of fact, studies show that women with PCOS
have a three-fold increased risk of developing endometrial
cancer (Chittenden et al., 2009; Fauser et al., 2012; Haoula
et al., 2012; Dumesic and Lobo, 2013) which is mostly
well differentiated with a good prognosis (Fauser et al.,
2012). Regardless, no data support ultrasound screening for
endometrial thickness in women with PCOS, which comes in
agreement with the American Cancer Society against screening
for endometrial cancer in patients with average or increased
risk. Yet women should be advised to notify their healthcare
provider for any spotting or unexpected bleeding (Smith et al.,
2001).
On the other hand, there are limited data to support
any association between PCOS and breast and ovarian cancer
(Chittenden et al., 2009; Fauser et al., 2012).
Psychological Wellbeing
Psychological stress and PCOS have been shown to be intimately
related. A vast number of studies showed that women with
PCOS are more prone to suffer from psychological disorders
such depression (Veltman-Verhulst et al., 2012), anxiety (Jedel
et al., 2010; Veltman-Verhulst et al., 2012), recreational drug-
related incidents (Hart and Doherty, 2015), disordered eating,
and psychosexual dysfunction (Deeks et al., 2010; Teede
et al., 2011) in comparison to healthy female controls. In
addition, females with PCOS have a lower self-esteem and
body satisfaction (Weiner et al., 2004; Himelein and Thatcher,
2006) and subsequently tend to have more psychiatric hospital
admissions than controls (Hart and Doherty, 2015). As a
result, they display a low quality of life (Jones et al., 2008;
Li et al., 2011; Fauser et al., 2012) and are prone to a
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high degree of emotional distress (Veltman-Verhulst et al.,
2012).
It is worth noting that obesity (Elsenbruch et al., 2003; Hahn
et al., 2005; Barnard et al., 2007), acne, hirsutism (Weiner et al.,
2004; Himelein and Thatcher, 2006) and irregular menstrual
cycles (Elsenbruch et al., 2006), all associated with PCOS, are
major contributors to the psychological stress that the patients
experience due to the challenging of the female identity and her
body image (Deeks et al., 2010; Teede et al., 2010, 2011; Dokras
et al., 2011; Legro et al., 2013).
Future research should focus the cause-effect relationship
between PCOS and psychiatric diseases and more attention
should be given to the psychological aspect of this disorder.
This is pertinent to clinical care as emotional disturbances can
unfavorably affect lifestyle management.
TREATMENT
Themanagement of PCOS targets the symptomatology for which
patients usually present, anovulation, infertility, hirsutism, or
acne being the most common complaints. Treatment usually
requires the corroboration of an interdisciplinary team that can
include a family practitioner, a gynecologist, and endocrinologist,
a dermatologist, a pediatrician, a psychiatrist, and a
psychologist.
The treatment section will mainly focus on two major
treatment guidelines: the American Task Force (Legro et al.,
2013) and the PCOS Australian Alliance Guidelines (Misso et al.,
2014).
Lifestyle Changes
Guidelines recommend exercise therapy and calorie-restricted
diet as a crucial part of the management of obesity in women
with PCOS. In fact, lifestyle modifications are considered as a
cost-effective first line treatment and as a necessary adjunct to
medication (Legro et al., 2013; Misso et al., 2014).
Excessive weight, as previously mentioned, is associated with
adverse metabolic and reproductive health outcomes in women
with PCOS. For instance, female fertility significantly decreases
with a BMI >30–32 kg/m2 (Teede et al., 2011). Multiple small
uncontrolled trials have shown that a body weight decrease of
as little as 5% regulates the menstrual cycle, improves fertility,
reduces insulin and testosterone levels, decreases the degree of
acne and hirsutism, and benefits psychological wellbeing (Clark
et al., 1998; Knowler et al., 2002; Pasquali et al., 2006; Norman
et al., 2007).
However, so far, neither a specific diet nor exercise
schedule has been shown to be superior to another in the
management of PCOS. In addition, it is difficult to ascertain
the effectiveness of such interventions based on the limited
data which sometimes address specific subgroups of women
with PCOS. Further studies are needed to compare the efficacy
of the different lifestyle management techniques (diet alone
or exercise alone in comparison to a combination of both)
with or without medical therapy for all associated clinical
outcomes.
Medical Treatment
If lifestyle changes are not enough to resolve symptomatology,
medical treatment is added for better management of the patient’s
complaints.
Oral Contraceptive Pills
OCP are the most commonly used medications for the long-term
treatment of women with PCOS and have been recommended
by the Task Force and the Endocrine Society (Legro et al.,
2013), the Australian Alliance (Misso et al., 2014), and the PCOS
Consensus Group (Fauser et al., 2012) as first-line treatment for
hyperandrogenism and menstrual cycle irregularities in women
with PCOS.
By suppressing the hypothalamo-pituitary-ovarian axis,
OCP decrease LH secretions, increase sex hormone binding
globulins, and decrease free testosterone levels (Costello et al.,
2007). This addresses hyperandrogenism-mediated symptoms
improving acne and hirsutism (Costello et al., 2007), corrects
menstrual cycle abnormalities, and provides a mean for effective
contraception (Yildiz, 2015). A minimum of 6 months of OCP
regimen is usually required to obtain satisfactory results against
acne and hirsutism (Yildiz, 2008a). Even though guidelines do
not specify the use of one OCP over another (Fauser et al., 2012;
Legro et al., 2013), the best choice for symptomatic treatment
is considered to be low-dose oral contraceptives that contain
anti-androgenic or neutral progestins (Yildiz, 2008a).
A number of clinical trials associated the use of OCP in
patients with PCOS with increased risk of insulin resistance
(Baillargeon et al., 2003; Legro et al., 2013). Concerns have
been also raised about the negative effects of OCP on the
cardiovascular profile of females with PCOS (Baillargeon et al.,
2005; Lidegaard et al., 2012). Nevertheless, data from randomized
control trials and observational studies demonstrated that OCP
are indeed effective and safe for the treatment of patients with
PCOS (Mendoza et al., 2014) with their benefits outweighing
their risks (Yildiz, 2008b).
Both guidelines recommend clomiphene citrate as first line
treatment of anovulatory infertility (Legro et al., 2013; Misso
et al., 2014). Exogenous gonadotropins, in vitro fertilization, and
laparoscopic ovarian drilling are considered as second line of
management (Spritzer et al., 2015) when clomiphene citrate with
or without metformin fail to achieve fertility.
Metformin
Metformin (Glucophage), an oral anti-diabetic biguanide drug,
acts by impeding hepatic glucose production and increasing the
peripheral insulin sensitivity (Bailey and Turner, 1996; Morin-
Papunen et al., 1998). The earliest studies on PCOS patients using
metformin were performed in 1994 by Velazquez et al. (1994);
the results revealed a 35% reduction in the insulin area and a 31%
decrease in insulin area to glucose ratio (Velazquez et al., 1994).
Some data revealed that metformin does not improve insulin
resistance itself, rather it improves glucose effectiveness, i.e., the
ability of glucose per se to repress endogenous glucose synthesis
and stimulate glucose uptake (Pau et al., 2014). Metformin
treatment of obese adolescents with PCOS and impaired glucose
tolerance proved beneficial in improving glucose tolerance and
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insulin sensitivity, in lowering insulinemia, and in reducing
elevated androgen levels (Arslanian et al., 2002).
In contrast, one study performed by Tang et al. showed
no significant change in insulin sensitivity in PCOS patients
receiving metformin. This could be explained by the high level
of obesity (BMI>30Kg/m2) and the limited weight loss the
patients in the study could attain (Tang et al., 2006). Similarly,
Ehrmann et al. showed that metformin did not improve insulin
resistance in PCOS women (Ehrmann et al., 1997). Acbay et al.
stated that metformin has no tangible effect on insulin resistance
in PCOS patients (Açbay and Gündog˘du, 1996). Even though
studies show contradictory results regarding metformin effect, it
is suggested as first-line treatment for cutaneous manifestations
and pregnancy complications in women with PCOS. It is also
used as a combination with clomiphene citrate to improve
fertility outcomes in clomiphene citrate resistant patients (Legro
et al., 2013; Misso et al., 2014).
Thiazolidinediones
Thiazolidinediones (TZD) represent a class of insulin sensitizer
drugs used in the treatment of type II diabetes mellitus. They
activate the gamma isoform of the peroxisome proliferator-
activated receptor, which is an adipocyte transcription factor
(Majuri et al., 2007). The use of pioglitazone (Actos
R©
), one
member of this class, was studied in patients with PCOS and
data showed that its administration results in a decline in fasting
serum insulin levels and insulin resistance (Brettenthaler et al.,
2004; Stabile et al., 2014). However, following the association
of pioglitazone with increased risk of bladder cancer (Lee and
Marcy, 2014; Levin et al., 2015), it has been recommended against
its use or the use of other TZDs (specifically troglitazone and
rosiglitazone) in the treatment of PCOS due to major safety
concerns (Legro et al., 2013).
Inositol
Recently, new drugs are being marketed as a novel treatment
of PCOS and are gaining more recognition due to their lack
of side effects. These are myo-inositol (MYO) and D-chiro-
inositol (DCI), 2 stereoisomers of inositol, an insulin-sensitizing
molecule.
Growing evidence suggests that insulin resistance might
be induced by an alteration of the metabolism of inositol
phosphoglycans (IPG) second messengers and mediators or by
a defect in their tissue availability (Baillargeon et al., 2008). Many
trials demonstrated that MYO administration improves insulin
resistance in PCOS patients (Galazis et al., 2011; Morgante et al.,
2011). One study reported that the decline in insulin resistance
is positively correlated with increasing fasting insulin plasma
levels, which supports the role of inositol as a modulator of
insulin-mediated metabolic pathway (Genazzani et al., 2012).
More recent studies assessed the effect of MYO in
combination with other new drugs. For instance, when
combined with monacolin K (natural statin) and lipoic acid,
inositol showed a dose-dependent improvement in dyslipidemia
and hyperandrogenism-associated symptoms (Morgante et al.,
2015). When combined with folic acid, MYO decreased
hyperstimulation syndrome to a higher extent than folic acid
alone in PCOS females undergoing oocyte retrieval (Papaleo
et al., 2009). MYO also improved reproductive outcomes in
those undergoing IVF when it was combined with α-lipoic
acid (Rago et al., 2015). More importantly, the combination
of MYO with DCI in a physiological plasma ratio of 40–1 led
to a decrease in the risk of developing metabolic syndrome in
obese women with PCOS (Nordio and Proietti, 2012). This has
been further reinforced by another study that showed significant
improvement in PCOS symptoms, in terms of more menstrual
cycle regularity, decreased insulin resistance, better lipid profile,
and less acne, upon the use of a MYO-DCI combination
(Formuso et al., 2015).
Therefore, a combination of MYO and DCI can be a
prospective therapeutic approach for the treatment of women
with PCOS. New large trials are needed to assess and compare
the effect of MYO and its various combinations to the classic
PCOS medications and to check for any undetected long-term
side effects.
Spironolactone
One study showed that spironolactone, a steroid chemically
related to the mineralocorticoid aldosterone, was able to improve
insulin sensitivity; it also suggested its use for hyperandrogenism-
associated symptoms such as acne and hirsutism (Ganie
et al., 2004). However, other studies failed to replicate these
results (Dunaif et al., 1990; Ganie et al., 2013). Accordingly,
guidelines do not provide any specific recommendations for
the use of spironolactone in the management of PCOS; further
methodological studies are required to assess any benefit, if
existent, for spironolactone in the treatment of this disease.
Treatment in Adolescents
So far, no placebo-controlled randomized controlled trials for
the treatment of PCOS in adolescents have been conducted.
As such, treatment recommendations mainly represent an
extrapolation of adult gathered data and are still highly
controversial. Recommendations suggest individualizing
treatment of adolescents with PCOS for benefits to outweigh
risks. However, these recommendations are not to be applied to
girls with precocious puberty due to unestablished risk-benefit
ratio in this population (Legro et al., 2013).
The mainstay of therapy for adolescents with PCOS is
OCPs, provided as both treatment of hyperandrogenism and as
an effective contraception method (Guttmann-Bauman, 2005;
Hillard, 2005; Diamanti-Kandarakis, 2010). OCPs normalize
menses and decrease acne and hirsutism (Cedars, 2004). Lifestyle
therapy and weight loss is also considered as part of the
first line treatment, especially in obese adolescents, as it also
improves acne and hirsutism. Nevertheless, uncertainty remains
regarding the best OCPs and their appropriate duration of use in
adolescents (Pfeifer and Dayal, 2003).
Alternatively, metformin has been shown to improve
hyperandrogenemia, menstrual irregularity, and insulin
resistance in obese and non-obese adolescents with PCOS
(Ibáñez et al., 2000; Arslanian et al., 2002; Pfeifer and Dayal,
2003). Yet, the necessary treatment period is still indefinite with
conflicting data showing a persistent effect of metformin for only
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3 months after discontinuation in one study (Ibáñez et al., 2000)
but up to 6 months in another (De Leo et al., 2006).
Finally, treatment of PCOS in adolescents is recommended
as OCPs may lower the chance of the patients to develop
hyperandrogenism in adulthood (Homburg and Lambalk, 2004)
and early lifestyle modifications and metformin therapy have
been associated with promising preventative results (Legro et al.,
2013).
SCREENING RECOMMENDATIONS
Appropriate care for the patient requires not only to treat
current symptoms but also to prevent any morbidity that might
develop later in the future, thus the importance of screening
recommendations as an essential part of the management of
PCOS. This section will shed light over what is recommended in
terms of screening for morbidities in patients with PCOS.
Screening for Type II DM
Women with PCOS should be routinely screened for type II DM.
Studies have shown that measurement of fasting blood glucose
levels alone under-diagnoses type II DM in patients with PCOS,
missing up to 80% of pre-diabetic and 50% of diabetic cases
(Salley et al., 2007). As such, guidelines currently recommend
screening women with PCOS using an oral glucose tolerance
test (Azziz et al., 2006). The screening could be done every 3–5
years (Legro et al., 2013), or every second year in patients with
no risk factors for type II DM and annually in patients with
risk factors (Misso et al., 2014). Examples of relevant risk factors
include age, gender, ethnicity, parental history of diabetes, history
of high blood glucose levels, use of antihypertensive medications,
smoking, physical inactivity, and waist circumference (Moran
et al., 2010).
Screening for CVD
Women with PCOS should be routinely screened for CVD risk
factors. Guidelines recommend cigarette smoking assessment,
body weight and BMI measurements to check for obesity,
blood pressure monitoring to evaluate for hypertension,
and a complete lipid profile panel (total cholesterol, low
density lipoprotein cholesterol LDL-C, high density lipoprotein
cholesterol HDL-C, and triglycerides levels) to screen for
dyslipidemia (Legro et al., 2013;Misso et al., 2014). It is important
to note that the Australian guideline dwells in depth in its
CVD screening recommendations, indorsing blood pressure
measurement annually if BMI ≤ 25 kg/m2 or at each visit if BMI
≥ 25 kg/m2 and lipid profile assessment every 2 years if initially
normal or every year if initially abnormal (Misso et al., 2014).
Screening for Psychological Wellbeing
Guidelines recommend screening women with PCOS should be
screened for not only depression and anxiety (Legro et al., 2013;
Misso et al., 2014) but also for negative body image, eating
disorders, and psychosexual dysfunction (Misso et al., 2014).
If screening is positive, the health physician should further
assess the problem and refer the patient to a specialist if needed.
CONCLUSION
An extended amount of knowledge has been learned about
PCOS since it was initially described by Stein and Leventhal
(1935). Yet, we are still lacking knowledge about many of
its aspects, including its etiology, progression throughout
life, spectrum of symptoms, and various morbidities. The
pathogenesis of PCOS remains obscure, with unregulated
steroidogenesis, insulin resistance, oxidative stress, and
genetic factors contributing, possibly from prenatal life, to
the disease. Supplementary studies are needed to bridge between
the various susceptibility factors that might contribute to
PCOS.
The current diagnostic guidelines are still vague and might
not detect patients with less severe non-classic phenotypes. The
guidelines in adolescents lack specificity, as they might fail to
differentiate between normal development and pathogenesis.
Since proper diagnosis is a crucial step to initiate treatment and
prevent future morbidities, further clinical research should seek
not only to update and unify guidelines but also to provide an
appropriate rationale for diagnostic tools that can detect all PCOS
phenotypes.
Morbidities, more common in the frank PCOS phenotype,
emphasize the complexity of this disease as a condition
that affects many bodily systems, whether endocrine,
gynecological, cardiac, or psychological. Therefore, the
management of this varied entity requires a skilled and
knowledgeable multidisciplinary team who can achieve best
patient outcomes. It is imperative to remember that the
treatment of PCOS changes throughout age and should be
guided by symptomatology. Early detection of long-term
morbidities through appropriate screening tests constitutes
an essential part of the management of this condition.
Guidelines strongly recommend lifestyle modifications
as a critical part of the management. OCPs are the main
medication of choice for anovulation and hyperandrogenism;
clomiphene citrate is the drug of choice for infertility.
Studies assessing inositol stereoisomers’ effectiveness should
carry on as they may become the new drug of choice for
treatment.
In conclusion, we hope this review provided an updated
summary that sheds light over the complex nature of PCOS.
Future research has to focus on themissing blocks in our growing
knowledge about this condition, for that physicians will be able to
provide the finest care for patients.
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